Filtered By:
Therapy: Stem Cell Therapy
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 697 results found since Jan 2013.
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
CONCLUSIONS: Two doses of DC:Ad-S, one given immediately before and another after ASCT, were feasible and safe. A high frequency of vaccine-specific immune responses was seen in combination with durable clinical outcomes, supporting ongoing investigation into the potential of this approach.PMID:37735756 | DOI:10.1158/1078-0432.CCR-22-3987
Source: Clinical Cancer Research - September 22, 2023 Category: Cancer & Oncology Authors: Ciara L Freeman Reginald Atkins Indumathy Varadarajan Meghan Menges Jeffrey Edelman Rachid Baz Jason Brayer Omar Castaneda Puglianini Jose Leonel Ochoa-Bayona Taiga Nishihori Kenneth H Shain Bijal Shah Dung Tsa Chen Linda Kelley Domenico Coppola Melissa A Source Type: research
Real-world challenges in eligibility for MMR vaccination two years after autologous and allogeneic HSCT
Vaccine. 2023 Aug 29:S0264-410X(23)00778-8. doi: 10.1016/j.vaccine.2023.06.075. Online ahead of print.ABSTRACTMeasles outbreaks have raised concerns of fatal infections in immunocompromised patients. Canadian guidelines advise administration of live vaccines, such as measles, mumps, and rubella (MMR), two yearsafter hematopoietic stem cell transplant (HSCT) yet studies have not assessed eligibility based on medication contraindications. We retrospectively reviewed the charts of 72 autologous (auto-HSCT) and 68 allogeneic (allo-HSCT) recipients at the Windsor Regional Cancer Center to determine MMR reactivity and eligibilit...
Source: Vaccine - August 31, 2023 Category: Allergy & Immunology Authors: Gopika Punchhi Rainbow Negus Hammad Saif Sharon Pritchard Olivia Owen Aman Sehmbi Caroline Hamm Source Type: research
Fight Aging! Newsletter, August 14th 2023
This study demonstrates just how vital the thymus is to maintaining adult health."
« Back to Top
Does Amyloid-β Aggregation Cause Broad Disruption of Proteostasis?
https://www.fightaging.org/archives/2023/08/does-amyloid-%ce%b2-aggregation-cause-broad-disruption-of-proteostasis/
Researchers here speculate on the ability of insoluble amyloid-β aggregates to be broadly disruptive of the solubility of many other proteins, and thus disruptive to cell and tissue function. Is this important in aging? The evidence here shows the existence of the mechanism in a lower species, but that doesn't n...
Source: Fight Aging! - August 13, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment
In this study, we demonstrate, for the first time, that treating established syngeneic murine colon and breast carcinoma tumors with a CSF1R-blocking antibody also promotes the expansion of neoepitope-specific T cells. To assess the role of tumor-derived CSF1 in these model systems, we generated and characterized CSF1 CRISPR-Cas9 knockouts. Eliminating tumor-derived CSF1 results in decreased tumor growth and enhanced immunity against tumor-associated neoepitopes, potentially promoting an immune permissive tumor microenvironment in tumor-bearing mice. The combination of neoepitope vaccine with anti-PDL1 in the MC38 CSF1-/- ...
Source: Cancer Control - July 28, 2023 Category: Cancer & Oncology Authors: Maria Del Mar Maldonado Jeffrey Schlom Duane H Hamilton Source Type: research
Vaccination of allogeneic haematopoietic stem cell transplant recipients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
Bull Cancer. 2023 Jul 19:S0007-4551(23)00289-8. doi: 10.1016/j.bulcan.2023.05.007. Online ahead of print.ABSTRACTDuring immune reconstitution following allogeneic haematopoietic stem cell transplantation (allo-HSCT), (re)vaccination of allo-HSCT recipients is recommended. Herein, we propose an update of practical recommendations regarding vaccination of allo-HSCT recipients. These recommendations, based on data from the literature, national and international guidelines and the consensus of the participants when no formally proven data are available, were elaborated during the workshop of practice harmonization organized by...
Source: Bulletin du Cancer - July 21, 2023 Category: Cancer & Oncology Authors: Anne Conrad Yves Beguin Sarah Guenounou Amandine Le Bourgeois Anne-Lise M énard Fanny Rialland Sharrouf Layal Anne-Claire Mamez Ibrahim Yakoub-Agha Jean El Cheikh Source Type: research
Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma
CONCLUSIONS: DC/MM fusion vaccination with lenalidomide did not result in a statistically significant increase in CR rates at 1-year post-transplant but was associated with a significant increase in circulating MM-reactive lymphocytes indicative of tumor-specific immunity. Site-specific production of a personalized cell therapy with centralized product characterization was effectively accomplished in the context of a multicenter cooperative group study.PMID:37463058 | DOI:10.1158/1078-0432.CCR-23-0235
Source: Clinical Lung Cancer - July 18, 2023 Category: Cancer & Oncology Authors: David J Chung Nina Shah Juan Wu Brent Logan Lina Bisharat Natalie Callander Giulia Cheloni Kenneth Anderson Thinle Chodon Binod Dhakal Steven Devine Poorvi Somaiya Dutt Yvonne Efebera Nancy Geller Haider Ghiasuddin Peiman Hematti Leona Holmberg Alan Howar Source Type: research
